Another small molecule inhibitor, avapritinib (Ayvakit®), was approved only for a subset of GIST that carry a certain PDGFRA (platelet-derived growth factor receptor alpha) mutation (PDGFRA D842V)13,14. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.